Does Rallies show 13F holders for NVO?

Yes. Rallies tracks hedge fund and 13F ownership data for NVO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NVO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NVO. It does not provide personalized investment advice.

NVO (Novo-Nordisk A/S) Stock Analysis - Hedge Fund Holdings

Novo-Nordisk A/S (NVO) is a publicly traded Healthcare sector company. As of May 20, 2026, NVO trades at $44.95 with a market cap of $196.24B and a P/E ratio of 0.00. NVO moved +1.77% today. Year to date, NVO is -18.22%; over the trailing twelve months it is -33.91%. Its 52-week range spans $35.12 to $121.34. Analyst consensus is neutral with an average price target of $43.00. Rallies surfaces NVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NVO stock?

Hedge funds tracked by Rallies that own NVO include Maverick Capital, Tiger Global, Farallon Capital, Coatue Management, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Novo-Nordisk A/S.

NVO Key Metrics

Key financial metrics for NVO
Metric	Value
Price	$44.95
Market Cap	$196.24B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	1.22%
52-Week High	$121.34
52-Week Low	$35.12
Volume	9.29M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding NVO

Maverick Capital holds 2.08M shares of NVO, changed +26401.73% as of Mar 31, 2026.
Tiger Global holds 1.27M shares of NVO, changed +0.00% as of Jun 30, 2025.
Farallon Capital holds 782.00K shares of NVO, changed +0.00% as of Mar 31, 2026.
Coatue Management holds 326.36K shares of NVO, changed +892.11% as of Sep 30, 2024.
Polen Capital holds 178.67K shares of NVO, changed -82.17% as of Jun 30, 2025.

Latest NVO News

Novo Nordisk Plans International Wegovy Launch After 2M US Prescriptions — May 18, 2026
High-Dose Wegovy Delivers 28% Weight Loss as Q1 Uptake Accelerates — May 13, 2026
Novo Nordisk GLP-1 Sales Hit DKK63.25B; Citigroup Lifts Target to DKK290 — May 12, 2026
Novo Nordisk’s High-Dose Wegovy Yields 28% Weight Loss, Hims & Hers Partnership — May 12, 2026
Novo Nordisk Transfers Parkinson’s Program to $60M-Funded AI Startup — May 11, 2026

NVO Analyst Consensus

8 analysts cover NVO: 0 strong buy, 1 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $43.00.

Common questions about NVO

Who owns NVO stock?: Hedge funds tracked by Rallies that own NVO include Maverick Capital, Tiger Global, Farallon Capital, Coatue Management, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Novo-Nordisk A/S.
Does Rallies show 13F holders for NVO?: Yes. Rallies tracks hedge fund and 13F ownership data for NVO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NVO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NVO. It does not provide personalized investment advice.